Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1)
This study is ongoing, but not recruiting participants.
Study NCT01030783 Information provided by AVEO Pharmaceuticals, Inc.
First Received on December 9, 2009. Last Updated on January 22, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Renal Cell Carcinoma
Additional conditions recognized in this trial
Carcinoma, Renal Cell
More general conditions related to this trial
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Interventions listed in this trial
More general drug interventions related to this trial
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Sponsors listed in this trial
AVEO Pharmaceuticals, Inc.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers